Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

References

• Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18:558–7. doi:10.1038/s41571-021-00507-y.
   PubMed Web of Science ®Google Scholar
• Hong WX, Haebe S, Lee AS, Westphalen CB, Norton JA, Jiang W, Levy R. Intratumoral immunotherapy for early-stage solid tumors. Clin Cancer Res. 2020;26:3091–3099. doi:10.1158/1078-0432.CCR-19-3642.
   PubMed Web of Science ®Google Scholar
• Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41:528–540. doi:10.1200/JCO.22.00343.
   PubMedGoogle Scholar
• Conwell J, Kirby J. Idera pharmaceuticals announces results from illuminate-301 trial of tilsotolimod + ipilimumab in anti-PD-1 refractory advanced melanoma. Aceragen. 2021.
   Google Scholar
• Melero I, Berraondo P, Rodríguez-Ruiz ME, Pérez-Gracia JL. Making the most of cancer surgery with neoadjuvant immunotherapy. Cancer Discov. 2016;6:1312–1314. doi:10.1158/2159-8290.CD-16-1109.
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O’Donnell JS, Allen S, Smyth MJ, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382–1399. doi:10.1158/2159-8290.CD-16-0577.
   PubMed Web of Science ®Google Scholar
• Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med. 2020;26:475–484. doi:10.1038/s41591-020-0829-0.
   PubMed Web of Science ®Google Scholar
• Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388:813–823.
   PubMed Web of Science ®Google Scholar
• Rosner S, Reuss JE, Zahurak M, Zhang J, Zeng Z, Taube J, Anagnostou V, Smith KN, Riemer J, Illei PB, et al. Five-Year clinical outcomes after neoadjuvant nivolumab in resectable non–small cell lung cancer. Clin Cancer Res. 2023;29:705–710. doi:10.1158/1078-0432.CCR-22-2994.
   PubMed Web of Science ®Google Scholar
• Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40:2924–2933. doi:10.1200/JCO.21.02660.
   PubMedGoogle Scholar
• Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363–2376. doi:10.1056/NEJMoa2201445.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Verschoor Y, van den Berg J, Sikorska K, Beets G, Lent AV, Grootscholten MC, Aalbers A, Buller N, Marsman H, et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Oncology Ao, Editor2022 Annals of Oncology. S808–69. 10.1016/j.annonc.2022.08.016
   Google Scholar
• Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, Sharma A, Treichel SA, Radcliffe H, Gorski KS, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021;27:1789–1796. doi:10.1038/s41591-021-01510-7.
   PubMed Web of Science ®Google Scholar
• Tormo D, Checińska A, Alonso-Curbelo D, Pérez-Guijarro E, Cañón E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megías D, Mulero F, et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell. 2009;16:103–114. doi:10.1016/j.ccr.2009.07.004.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell KM, Funes JM, Vega-Crespo A, Parisi G, Champekar A, Nguyen C, et al. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med. 2020;12. doi:10.1126/scitranslmed.abb0152.
   PubMed Web of Science ®Google Scholar
• Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberría I, Perez G, Rodriguez I, Bolaños E, Lopez-Casas P, et al. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J Immunother Cancer. 2019;7:116. doi:10.1186/s40425-019-0568-2.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Molina C, De Andrea CE, Fernandez-Sendin M, Villalba M, Gonzalez-Gomariz J, Ochoa MC, Teijeira A, Glez-Vaz J, Aranda F, et al. Intratumoral co-injection of the poly I: c-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. J ImmunoTher Cancer. 2021;9:e002953. doi:10.1136/jitc-2021-002953.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ruiz ME, Serrano-Mendioroz I, Garate-Soraluze E, Sánchez-Mateos P, Barrio-Alonso C, Rodríguez López I, Diaz Pascual V, Arbea Moreno L, Alvarez M, Sanmamed MF, et al. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control. J ImmunoTher Cancer. 2023;11:11. doi:10.1136/jitc-2022-005011.
   Web of Science ®Google Scholar
• Márquez-Rodas I, Longo F, Rodriguez-Ruiz ME, Calles A, Ponce S, Jove M, Rubio-Viqueira B, Perez-Gracia JL, Gómez-Rueda A, López-Tarruella S, et al. Intratumoral nanoplexed poly I: c BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors. Sci Transl Med. 2020;12. doi:10.1126/scitranslmed.abb0391.
   PubMed Web of Science ®Google Scholar
• Márquez-Rodas I, Dutriaux C, Saiag P, Merino, 2022. Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: final results of SPOTLIGHT203 phase 2 study 2022. New Orleans:AACR
   Google Scholar
• Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, et al. Batf3 deficiency reveals a critical role for CD8α + dendritic cells in cytotoxic T cell immunity. Science. 2008;322:1097–1100. doi:10.1126/science.1164206.
   PubMed Web of Science ®Google Scholar
• Aiken TJ, Komjathy D, Rodriguez M, Stuckwisch A, Feils A, Subbotin V, Birstler J, Gillies SD, Rakhmilevich AL, Erbe AK, et al. Short-course neoadjuvant in situ vaccination for murine melanoma. J ImmunoTher Cancer. 2022;10:e003586. doi:10.1136/jitc-2021-003586.
   PubMed Web of Science ®Google Scholar
• Etxeberria I, Bolaños E, Quetglas JI, Gros A, Villanueva A, Palomero J, Sánchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, et al. Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8. Cancer Cell. 2019;36:613–29.e7. doi:10.1016/j.ccell.2019.10.006.
   PubMed Web of Science ®Google Scholar
• Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–682. doi:10.1038/nmeth.2019.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24. doi:10.1038/s41577-019-0210-z.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487–500. doi:10.1038/s41590-022-01132-2.
   PubMed Web of Science ®Google Scholar
• van Pul Km, Notohardjo JCL, Fransen MF, Koster BD, Stam AGM, Chondronasiou D, van Pul KM, Lougheed SM, Bakker J, Kandiah V, et al. Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation. Sci Immunol. 2022;7:eabn8097. doi:10.1126/sciimmunol.abn8097.
   PubMed Web of Science ®Google Scholar